Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jan;6(1):21-7.
doi: 10.1215/s1152851703000218.

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11

Tracy T Batchelor  1 , Mark R Gilbert, Jeffrey G Supko, Kathryn A Carson, Louis B Nabors, Stuart A Grossman, Glenn J Lesser, Tom Mikkelsen, Surasak Phuphanich; NABTT CNS Consortium
Affiliations
Clinical Trial

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11

Tracy T Batchelor et al. Neuro Oncol. 2004 Jan.

Abstract

The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurrent malignant glioma who were treated with irinotecan. Secondary objectives were to determine progression-free survival, overall survival, and toxicity. The trial was terminated after the first 18 patients were enrolled in this multicenter, 2-stage, phase 2 study. Twelve patients received concurrent enzyme-inducing antiepileptic drugs, and 6 did not. Each cycle consisted of a 90-min i.v. infusion of irinotecan every week for 4 consecutive weeks, followed by 2 weeks off. One patient had a complete response, 5 patients had stable disease, 5 patients had radiographic progression, 6 patients were removed from the study because of toxicity, and 1 patient refused further therapy and was removed from the study. The response rate in this study was 6% (1/18), and 28% (5/18) of these patients progressed while receiving irinotecan. Dose-limiting toxicities consisted of diarrhea in 5 patients, neutropenia in 1 patient, infection in 1 patient, and respiratory failure in 1 patient. Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Axial (L) and coronal (R) MRI images of the 1 patient who had a complete response. Top Panels. Prechemotherapy, contrast-enhanced, T1-weighted axial and coronal magnetic resonance images demonstrate heterogeneous enhancement of the tumor in the left temporal lobe. Bottom Panels. The enhancement has resolved after CPT-11 therapy, consistent with a complete response.
Fig. 2
Fig. 2
Kaplan-Meier curve of overall survival (solid line) and progression-free survival (broken line) of the 18 patients with recurrent glioma.
See this image and copyright information in PMC

References

    1. Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol. 1996;7:837–842. - PubMed
    1. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective. Eur J Cancer. 1996;32A:S18–S23. - PubMed
    1. CBTRUS. Central Brain Tumor Registry of the United States (2002). Statistical Report: Primary Brain Tumors in the United States, 1995 –1999. Chicago: Central Brain Tumor Registry of the United States (available at http://www.cbtrus.org/2002/2002report.pdf).
    1. Cloughesy T, Filka E, Friedman H, Kabbinavar F, Kuhn J, Selch M, Miller L. A phase I (intrapatient dose escalation) open-label study of irinotecan (CPT-11) in patients with recurrent or progressive malignant glioma. 19. 2000;Proc Am Soc Clin Oncol:161a. (abstract)
    1. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998;41:485–490. - PubMed

Publication types

MeSH terms